Therapeutic vaccines against HPV16-associated tumors: Minireview

Neoplasma

Volumn 49, Issue 5, 2002, Pages 285-289

  Bubenik J ^a  

^a INSTITUTE OF MATHEMATICS   (Czech Republic)

Author keywords

Dendritic cells; Human papilloma viruses; Interleukins; Tumor vaccines

Indexed keywords

DNA VACCINE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MEMBRANE PROTEIN; ONCOPROTEIN; POLYNUCLEOTIDE; PROTEIN E6; PROTEIN E7; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE; VIRUS VECTOR;

CANCER CELL; CANCER PREVENTION; CANCER RISK; CANCER TISSUE; CARCINOGENICITY; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; GENE GUN; GENETIC CODE; GENETIC TRANSFECTION; HUMAN; IMMUNIZATION; IMMUNOLOGICAL TECHNIQUE; MALIGNANT TRANSFORMATION; NONHUMAN; ONCOGENE; PHENOTYPE; PROTEIN EXPRESSION; SHORT SURVEY; TUMOR MODEL; UTERINE CERVIX CARCINOMA; VIRUS CARCINOGENESIS; VIRUS CLASSIFICATION; VIRUS DETECTION; WART VIRUS;

EID: 0036450232     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (50)

1. Bauer S, Heeg K, Wagner H, Lipford GB. Identification of H-2Kb binding and immunogenic peptides from human papilloma virus tumour antigens E6 and E7. Scand J Immunol 1995; 42: 317-323.
2. Bontkes HJ, Walboomers JMM, Meijer CJLM, Helmerhorst TJM, Stern PL. Specific HLA class I down-regulation is an early event in cervical dysplasia associated with clinical progression. Lancet 1998; 351: 187-188.
3. Bubeník J. Animal models for development of therapeutic HPV16 vaccines. Int J Oncol 2002; 20: 207-212.
4. Bubeník J. Dendritic cell-based cancer vaccines. Folia Biol (Praha) 1999; 45: 71-74.
5. Bubeník J. Genetically modified dendritic cell-based cancer vaccines. Folia Biol (Praha) 2001; 47: 153-155.
6. Bubeník J. Genetically modified dendritic cell-based tumour vaccines. Int J Oncol 2001; 18: 475-478.
7. Bubeník J. Utilization of oncoprotein-pulsed dendritic cells as tumour vaccines. J Cancer Res Clin Oncol 2001; 127: 463-466.
8. Bubeník J. Granulocyte-macrophage colony-stimulating factor gene-modified vaccines for immunotherapy of cancer. Folia Biol (Praha) 1999; 45: 115-119.
9. Bubeník J, Mikyšková R, Vonka V, Mendoza L, Šímová J, Šmahel M, Inorová M. Interleukin 2 and dendritic cells as adjuvants for surgical therapy of tumours associated with Human Papillomavirus type 16. Vaccine (in press).
10. Bubeník J, Šímová J, Hájková R, Sobota V, Jandlová T, Šmahel M, Sobotková E, Vonka V. Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV16. Int J Oncol 1999; 14: 593-597.
11. Bubeník J, Šímová J, Vondrys P, Vonka R, Kitasato H, Boštík P, Vonka V. IL-2 as adjuvant for vaccination with cells malignantly converted by HPV16 or 3-MC. Int J Oncol 1996; 8: 477-481.
12. Chang EY, Chen C-H, Ji H, Wang T-L, Hung K, Lee BP, Huang AYC, Kurman RJ, Pardoll DM, Wu T-C. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine. Int J Cancer 2000; 86: 725-730.
13. Chen C-H, Ji H, Suh KW, Choti MA, Pardoll DM, Wu T-C. Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs. Gene Ther 1999; 6: 1972-1981.
14. Chen L, Mizuno MT, Singhal MC, Hu S-L, Galloway DA, Hellström I, Hellström KE. Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J Immunol 1992; 148:2617-2621.
15. Chen L, Thomas EK, Hu S-L, Hellström I, Hellström KE. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci 1991; 88: 110-114.
16. Chu NR, Wu HB, Wu T-C, Boux LJ, Siegel MI, Mizzen LA. Immunotherapy of a human papillomavirus (HPV)(1-fPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp 65 and HPV16 E7. Clin Exp Immunol 2000; 121: 216-225.
17. Connor ME, Stern PL. Loss of MHC class-I expression in cervical carcinomas. Int J Cancer 1990; 46:1029-1034.
18. Daemen T, Pries F, Bungener L, Kraak M, Regts J, Wilschut J. Genetic immunization against cervical carcinoma: Induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7. Gene Ther 2000; 7: 1859-1866.
19. Feltkamp MC, Smits HL, Vierboom MPM, Minnaar RP, de Jongh BM, Drijfhout JW, ter Schegget J, Melief CJM, Kast WM. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993; 23: 2242-2249.
20. Feltkamp MCW, Vreugdenhil GR, Vierboom MPM, Ras E, van der Burg SH, Ter Schegget J, Melief CJM, Kast WM. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur J Immunol 1995; 25: 2638-2642.
21. Fernando GJP, Murray B, Zhan J, Fraser JH. Expression, purification and immunological characterization of the transforming protein E7 from cervical cancer-associated human papillomavirus type 16. Clin Exp Immunol 1999; 115: 397-403.
22. Gao L, Chain B, Sinclair C, Crawford L, Zhou J, Morris J, Zhu X, Strauss H. Immune response to human papillomavirus type 16 E6 gene in a live vaccinia vector. J Gen Virol 1994; 75: 157-164.
23. Greenstone HL, Nieland JD, de Visser KE, de Bruijn MLH, Kirnbauer R, Roden RBS, Lowy DR, Kast WM, Schiller JT. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci USA 1998; 95: 1800-1805.
24. Hájková R, Indrová M, Jandlová T, Bubeník J, Reiniš M. Interleukin 2 gene therapy of surgical minimal residual tumour disease: Characterization of cytolytic effector cells from tumour progressors and regressors. Folia Biol (Praha) 1999; 45: 227-231.
25. Hallez S, Detremmerie O, Giannouli C, Thielemans K, Gajewski TF, Burny A, Leo O. Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity. Int J Cancer 1999; 81: 428-437.
26. Hariharan K, Braslawsky G, Barnett RS, Berquist LG, Huynh T, Hanna N, Black A. Tumor regression in mice following vaccination with human papillomavirus E7 recombinant protein in PROVAX. Int J Oncol 1998; 12: 1229-1235.
27. Indrová M, Bubeník J, Mikyšková R, Vonka V, Šmahel M, Žak R, Šímová J, Bieblová J, Mendoza L, Jandlová T. Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I-tumours of HPV16 origin. Int J Oncol 2002; 20: 643-646.
28. Indrová M, Bubeník J, Šímová J, Vonka V, Němečková S, Mendoza L, Reiniš M. Therapy of HPV16-associated carcinoma with dendritic cell-based vaccines: In vitro priming of the effector cell responses by DC pulsed with tumour lysates and synthetic RAHYNIVTF peptide. Int J Mol Med 2001; 7: 97-100.
29. Indrová M, Pajtasz-Piasecka E, Jandlová T, Šímová J, Bubeník J, Radzikowski C. IL-2 gene-modified tumour vaccines: Monitoring of IL-2 levels in serum and peritoneal cavity of vaccinated mice. Folia Biol (Praha) 1999; 45: 7-11.
30. Ji H, Wang T-L, Chen C-H, Pai SI, Hung C-F, Lin K-Y, Kurman RJ, Pardoll DM, Wu T-C. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum Gene Ther 1999; 10: 2727-2740.
31. Lin K-Y, Guarnieri FG, Staveley-O'Carrol KF, Levitsky HI, August JT, Pardoll DM, Wu T-C. Treatment ofestablished tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56: 21-26.
32. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief C-J, Ildstad ST, Kast WM, de Leo AB, Lotze MT. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med 1995; 1: 1297-1302.
33. Mendoza L, Bubeník J, Šímová J, Korb J, Bieblová J, Vonka V, Indrová M, Mikyšková R, Jandlová T. Tumour-inhibitory effects of dendritic cells administered at the site of HPV16-induced neoplasms. Folia Biol (Praha) 2002; 47: 113-118.
34. Mendoza L, Indrová M, Hájková R, Reiniš M, Šmahel M, Vonka V, Bubeník J, Jandlová T. Peritumoral administration of antigen-unstimulated bone marrow-derived dendritic cells inhibits tumour growth. Foli Biol (Praha) 2000; 46: 91-97.
35. Meneguzzi G, Cerni C, Kieny MP, Lathe R. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology 1991; 181: 62-69.
36. Mikyšková R, Bubeník J, Mendoza L, Vonka V, Šmahel M, Šímová J, Jandlová T. Local cytokine treatment of HPV16-associated tumours results in inhibition of their lung metastases. Clin Exp Metastasis 2001; 18: 581-587.
37. Ossevoort MA, Feltkamp MCW, van Veen KJH, Melief CJM, Kast WM. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother 1995; 18: 86-94.
38. Rössner P, Bubeník J, Indrová M, Sobota V, Vondrys P, Zeuthen J, Jandlová T, Takáč M. Genetically modified tumour vaccines: Insertion of the IL-2 gene down-regulates tumorigenicity more efficiently than insertion of the CD80 gene. Int J Oncol 1997; 10: 77-82.
39. Rössner P, Bubeník J, Sobota V, Indrová M, Hájková R, Mendoza L, Jandlová T, Šímová J. Granulocyte-macrophage colony-stimulating factor-producing tumour vaccines. Folia Biol (Praha) 1999; 45: 173-177.
40. Shi W, Bu P, Liu J, Polack A, Fisher S, Qiao L. Human papillomavirus type 16 E7 DNA vaccine: Mutation in the open reading frame of E7 enhances specific cytotoxic Tlymphocyte induction and antitumor activity. J Virol 1999; 73: 7877-7881.
41. Šímová J, Reiniš M, Sobota V, Čapková J, Bubeník J, Jandlová T. Irradiation of genetically modified plasmacytoma vaccines results in upregulation of CD80 molecule expression, IL-2 production and higher therapeutic efficacy of the vaccine. Folia Biol (Praha) 2000; 46: 11-16.
42. Šmahel M, Šíma P, Ludvíková V, Vonka V. Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 2001; 281: 231-238.
43. Šmahel M, Sobotková E, Bubeník J, Šímová J, Žák R, Ludvíková V, Hájková R, Kovarík J, Jelínek F, Povýšil C, Marinov J, Vonka V. Metastatic MHC class I-negative mouse cells derived by transformation with human papillomavirus type16. Brit J Cancer 2001; 84: 374-380.
44. Sobota V, Bubeník J, Šímová J, Jandlová T. Intratumoral IL-2 gene transfer improves the therapeutic efficacy of IL-12 but not IL-18. Folia Biol (Praha) 2000; 46: 191-193.
45. Tüting T, de Leo AB, Lotze MT, Storkus WJ. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. Eur J Immunol 1997; 27: 2702-2707.
46. Tüting T, Gambotto A, de Leo A, Lotze MT, Robbins PD, Storkus WJ. Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. Cancer Gene Ther 1999; 6: 73-80.
47. Vonka V, Sobotková E, Hamšíková E, Šmahel M, Žák R, Kitasato H, Sainerová H. Induction of anti-tumour immunity by suicide-gene-modified HPV-16-transformed hamster cells. Int J Cancer 1998; 77: 470-475.
48. Walboomers JM, Jacobs MV, Manos MM, Bosch F, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.
49. Wang T-L, Ling M, Shih I-M, Pham T, Pai SI, Lu Z, Kuorman RJ, Pardoll DM, Wu T-C. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther 2000; 7: 726-733.
50. d mice. Scand J Immunol 1995; 42: 557-563.